Allogene Therapeutics Inc
NASDAQ:ALLO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
US |
|
Enterprise Financial Services Corp
NASDAQ:EFSC
|
US |
|
S
|
Sogefi SpA
MIL:SO
|
IT |
|
Samyung Trading Co Ltd
KRX:002810
|
KR |
|
C
|
Chow Tai Seng Jewellery Co Ltd
SZSE:002867
|
CN |
|
Abattis Bioceuticals Corp
OTC:ATTBF
|
CA |
|
L
|
Latitude Group Holdings Ltd
ASX:LFS
|
AU |
|
K
|
Kforce Inc
F:ROF
|
US |
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 310 full-time employees. The company went IPO on 2018-10-11. The firm is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715 plus nirogacestat, ALLO-605, ALLO-316, and ALLO-647.
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 310 full-time employees. The company went IPO on 2018-10-11. The firm is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715 plus nirogacestat, ALLO-605, ALLO-316, and ALLO-647.
Data timing: Interim MRD futility results from ALPHA3 (24 patients: 12 per arm) are expected in April 2026; proof-of-concept translational and early clinical data for ALLO-329 are expected in June 2026.
Primary focus: Allogene is prioritizing two programs — Cema-Cel in the ALPHA3 randomized MRD-guided consolidation study in first-line large B‑cell lymphoma and ALLO-329 for autoimmune disease — and has extended runway into Q1 2028 to execute them.
ALPHA3 readout goal: Management has anchored a meaningful MRD clearance delta at an absolute 25%–30% between arms as the threshold they view as clinically important at the April analysis.
ALLO-329 profile: ALLO-329 is a dual CD19/CD70 allogeneic CAR T using the Dagger technology designed to enable activity at low (or no) lymphodepletion; initial cohort dose is 20 million cells.
Community adoption: ALPHA3 is active at over 60 U.S./Canada sites (~50/50 community and academic); several community centers that were CAR‑T naive are successfully administering Cema-Cel.
Finances & guidance: Cash and investments were $258.3 million at 12/31/2025, additional $23.7 million received from escrow, $20.7 million raised via ATM year-to-date, and the company expects operating cash expense ≈ $150 million and operating expenses ≈ $210 million in 2026 (including ≈ $35 million stock-based compensation).
